Table 1 : Subject characteristics.


  Simvastatin (n=15) Placebo (n=15)

Age (years) 51(30–64)** 49(37–65)**

Menopause

Pre 8 8
Post 7 7
Body Mass Index (kg/m2) 24.7(15.5–30.5)** 26.2(21.09–34.9)**
Total Blood Cholesterol (mg/dL) 204.4(138–282)** 214(144–327)**

Blood Cholesterol

Normal 5 9
Elevated 10 6

Stage

IIA -- 1
IIB 9 8
IIIA 6 6

Grade

Low 8 7
High 7 8

Tumor Type

Ductal 5 9
Lobular 1 2
Mixed 9 4
Length of Therapy (day) 32 (28–39)** 32 (28–47)**

ER/PR

Positive 10 8
Negative 5 7

HER-2

Amplification 9 6
 No amplification 6 9
Ki67(%) 75(30–90)** 30(15–40)**
Migration Index
(absorbance level)
1.44±0.31* 0.953±0.23*
RhoC (ng/µL) 0.15(0.05–2.33)** 0.14(0.08–1.48)**
CD44 ng/µL) 6.54(0.97–99.55)** 14.31(0.5–293.32)**
CXCR4 (ng/µL) 12.89(0.46–81.83)** 14.94(1.35–30.06)**
ROCK (ng/µL) 0.9633±0.608* 0.6235±0.275*

*Mean±SD
**Median (minimum–maximum)

Yulian et al.Journal of Cancer Therapeutics and Research  2016 5:10DOI : 10.7243/2049-7962-5-10